[go: up one dir, main page]

CL2016001739A1 - Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2. - Google Patents

Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.

Info

Publication number
CL2016001739A1
CL2016001739A1 CL2016001739A CL2016001739A CL2016001739A1 CL 2016001739 A1 CL2016001739 A1 CL 2016001739A1 CL 2016001739 A CL2016001739 A CL 2016001739A CL 2016001739 A CL2016001739 A CL 2016001739A CL 2016001739 A1 CL2016001739 A1 CL 2016001739A1
Authority
CL
Chile
Prior art keywords
imidazol1
mglur4
emesis
neuroprotection
autism
Prior art date
Application number
CL2016001739A
Other languages
English (en)
Inventor
Wolfgang Guba
Georg Jaeschke
Antonio Ricci
Daniel Rueher
Eric Viera
Barbara Biemans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016001739A1 publication Critical patent/CL2016001739A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5H-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos MAP del receptor metabotrópico del glutamato 4 mGluR4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del Parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.
CL2016001739A 2014-01-10 2016-07-07 Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2. CL2016001739A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14150700 2014-01-10

Publications (1)

Publication Number Publication Date
CL2016001739A1 true CL2016001739A1 (es) 2017-05-12

Family

ID=49917002

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001739A CL2016001739A1 (es) 2014-01-10 2016-07-07 Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.

Country Status (21)

Country Link
US (1) US9695128B2 (es)
EP (1) EP3092219B1 (es)
JP (1) JP6263633B2 (es)
KR (1) KR101868248B1 (es)
CN (1) CN106170479B (es)
AR (1) AR099047A1 (es)
AU (1) AU2015205661B2 (es)
BR (1) BR112016010168A2 (es)
CA (1) CA2934768A1 (es)
CL (1) CL2016001739A1 (es)
CR (1) CR20160198A (es)
EA (1) EA029967B1 (es)
IL (1) IL245327B (es)
MX (1) MX369820B (es)
PE (1) PE20160860A1 (es)
PH (1) PH12016501100B1 (es)
SG (1) SG11201605557TA (es)
TW (1) TWI649310B (es)
UA (1) UA119053C2 (es)
WO (1) WO2015104271A1 (es)
ZA (1) ZA201602890B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117855C2 (uk) * 2014-02-25 2018-10-10 Ф. Хоффманн-Ля Рош Аг Похідні етинілу
HUE045145T2 (hu) 2015-07-15 2019-12-30 Hoffmann La Roche Etinil-származékok metabotróp glutamátreceptor-modulátorokként
AR105556A1 (es) 2015-08-03 2017-10-18 Hoffmann La Roche Derivados de etinilo
JP6936305B2 (ja) 2016-07-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エチニル誘導体
EP3668873B1 (en) * 2017-08-17 2021-06-30 F. Hoffmann-La Roche AG Imidazo[1,2-a]imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease
US10893929B2 (en) 2018-01-10 2021-01-19 Cook Medical Technologies Llc Vascular graft with compartments for compliance matching
US10517713B2 (en) 2018-01-10 2019-12-31 Cook Medical Technologies Llc Vascular graft with helical flow compliance compartments
CN112566906B (zh) 2018-07-26 2024-11-12 多曼治疗学公司 取代的喹唑啉酮衍生物和它们作为mglur4的正变构调节剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581817A (en) * 2007-06-03 2012-05-25 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
IN2012DN02580A (es) * 2009-09-04 2015-08-28 Univ Vanderbilt
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US10533000B2 (en) * 2011-05-26 2020-01-14 Sunovion Pharmaceuticals, Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof

Also Published As

Publication number Publication date
IL245327A0 (en) 2016-06-30
MX369820B (es) 2019-11-22
KR101868248B1 (ko) 2018-06-15
MX2016008887A (es) 2016-10-04
CR20160198A (es) 2016-06-17
AR099047A1 (es) 2016-06-22
AU2015205661B2 (en) 2018-08-23
HK1226054A1 (zh) 2017-09-22
TW201531464A (zh) 2015-08-16
BR112016010168A2 (pt) 2017-08-08
EA029967B1 (ru) 2018-06-29
EP3092219B1 (en) 2018-09-19
EA201691046A1 (ru) 2016-12-30
JP6263633B2 (ja) 2018-01-17
CA2934768A1 (en) 2015-07-16
WO2015104271A1 (en) 2015-07-16
KR20160095099A (ko) 2016-08-10
TWI649310B (zh) 2019-02-01
PH12016501100A1 (en) 2016-07-11
CN106170479A (zh) 2016-11-30
UA119053C2 (uk) 2019-04-25
JP2017502066A (ja) 2017-01-19
US20170008854A1 (en) 2017-01-12
PH12016501100B1 (en) 2016-07-11
PE20160860A1 (es) 2016-09-03
SG11201605557TA (en) 2016-08-30
US9695128B2 (en) 2017-07-04
EP3092219A1 (en) 2016-11-16
IL245327B (en) 2018-12-31
CN106170479B (zh) 2019-02-12
ZA201602890B (en) 2017-07-26

Similar Documents

Publication Publication Date Title
CL2016001739A1 (es) Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018001556A1 (es) Receptores de antígenos quiméricos (car) de bcma. (solicitud divisional 201701515)
CL2018002697A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos.
PH12017500920A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ737399A (en) Ccr2 modulators
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
MD20160109A2 (ro) Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
CL2016002064A1 (es) Derivados de etinilo.
MX2017003288A (es) Metodos para preparar modulares de receptor tipo toll.
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.